与发育性和性脑病相关的 - 自闭症表型:基于机制的新疗法选择
Nicola Specchio1,2, Valentina Di Micco1, Eleonora Aronica3,4
1Neurology Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, full member of EpiCARE, Rome, Italy.
Epilepsia
|February 22, 2025
概括
了解和自闭症在遗传发育和脑病变 (DEE) 中的神经生物学是开发新治疗方法的关键. 遗传学和早期干预方面的进展为患有DEE和自闭症的儿童提供了改善结果的希望.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 发展生物学 发展生物学
背景情况:
- 和自闭症在遗传发育和性脑病变 (DEE) 中经常同时发生,这带来了复杂的诊断和治疗挑战.
- 连接这些疾病的潜在神经生物学机制尚未完全理解,这阻碍了开发有效的基于机制的疗法.
- 最近的遗传发现已经确定了与DEE,智力障碍和自闭症特征相关的新基因,突出显示了临床异质性.
研究的目的:
- 探索神经生物学途径和遗传因素,这些因素是DEE中和自闭症的共同发生的基础.
- 审查针对 - 自闭症表型相关的特定分子和细胞机制的新兴治疗策略.
- 强调早期干预和精确健康方法的重要性,以改善受影响儿童的神经发育结果.
主要方法:
- 关于DEE遗传原因及其与自闭症谱系障碍特征相关的当前文献的综述.
- 神经生物学机制的分析,包括GABAergic信号传递,突触可塑性,功能连接性,mTOR通路和神经炎症.
- 检查新兴和个性化的治疗选择,包括基因变异特异性疗法和早期干预策略.
主要成果:
- 多个基因 (例如,PPFIA3,MYCBP2,KCNQ2,SCN1A) 与 - 自闭症表型的DEE有关,表明不同的遗传病因.
- 关键的共同机制包括GABAergic系统失调,mTOR通路异常,神经炎症以及突触功能和连接的破坏.
- 针对离子通道 (KCNQ,KCNT1) 和通道 (mTOR) 的新兴治疗方法有希望,但反应异质,需要个性化方法.
结论:
- 了解遗传,表观遗传和环境因素的复杂相互作用对于破译DEE中的-自闭症表型至关重要.
- 精准医学,包括早期诊断和基于特定遗传变异和受影响途径的向治疗,是必不可少的.
- 持续的研究和精心设计的临床试验,专注于基于机制的干预措施和早期行为支持,对于改善患者的治疗结果至关重要.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.5K
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
20.1K
相关概念视频
01:24Arteries of the Lower Limbs
176
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
176
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
309
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
309
01:14Antiepileptic Drugs: Glutamate Antagonists
270
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
270
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209
01:19Autism Spectrum Disorder
56
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
56
01:20Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140